BMO starts Intuitive Surgical initiated with an Outperform on durable earnings
As previously reported, BMO Capital analyst Vik Chopra initiated coverage of Intuitive Surgical with an Outperform rating and $518 price target. The da Vinci 5 upgrade cycle is still in early innings, procedure growth is broadening into new specialties and geographies, and the earnings stream is "durable and visible," the analyst tells investors.
As previously reported, BMO Capital analyst Vik Chopra initiated coverage of Intuitive Surgical with an Outperform rating and $518 price target.
The da Vinci 5 upgrade cycle is still in early innings, procedure growth is broadening into new specialties and geographies, and the earnings stream is "durable and visible," the analyst tells investors.